^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    becotarug (JMT101)

    i
    Other names: JMT101
    Company:
    CSPC Pharma
    Drug class:
    EGFR inhibitor
    Related drugs:
    7ms
    JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations (clinicaltrials.gov)
    P2, N=161, Active, not recruiting, Shanghai JMT-Bio Inc.
    New P2 trial
    |
    Tagrisso (osimertinib) • becotarug (JMT101)
    7ms
    JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations (clinicaltrials.gov)
    P3, N=398, Not yet recruiting, Shanghai JMT-Bio Inc.
    New P3 trial • Combination therapy • EGFR exon 20 • Metastases
    |
    cisplatin • Tagrisso (osimertinib) • pemetrexed • becotarug (JMT101)
    8ms
    Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2/3, N=534, Not yet recruiting, Shanghai JMT-Bio Inc.
    New P2/3 trial
    |
    docetaxel • becotarug (JMT101)
    1year
    A Study of JMT101 in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=102, Not yet recruiting, Shanghai JMT-Bio Inc.
    New P2 trial • Metastases
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    MSI-H/dMMR • BRAF wild-type
    |
    Stivarga (regorafenib) • irinotecan • becotarug (JMT101)
    over1year
    Phase 1b trial of anti-EGFR antibody JMT101 and Osimertinib in EGFR exon 20 insertion-positive non-small-cell lung cancer. (PubMed, Nat Commun)
    Intracranial disease control rate is 87.5%. Confirmed intracranial objective response rate is 25%.
    P1 data • Journal • EGFR exon 20
    |
    EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    Tagrisso (osimertinib) • becotarug (JMT101)
    almost3years
    Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=155, Not yet recruiting, Shanghai JMT-Bio Inc.
    Clinical • New P2 trial • EGFR exon 20
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    Tagrisso (osimertinib) • becotarug (JMT101)
    over3years
    [VIRTUAL] JMT101 Combined With Afatinib or Osimertinib in Patients (pts) With NSCLC With EGFR Exon 20 Insertion Mutations (IASLC-WCLC 2021)
    The abstract for this presentation has not been submitted or is currently under embargo until August 18, 2021 at 16:00 MDT.
    Clinical • EGFR exon 20
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    Tagrisso (osimertinib) • Gilotrif (afatinib) • becotarug (JMT101)
    almost4years
    Efficacy and Safety of JMT101 in Patients With Advanced Solid Tumor (clinicaltrials.gov)
    P1, N=259, Recruiting, Shanghai JMT-Bio Inc.
    Clinical • New P1 trial
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600
    |
    5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • becotarug (JMT101)
    over4years
    Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=48, Recruiting, Shanghai JMT-Bio Inc. | Not yet recruiting --> Recruiting
    Clinical • Enrollment open • EGFR exon 20
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    Tagrisso (osimertinib) • Gilotrif (afatinib) • becotarug (JMT101)